Biggest Diabetes Tech & Research Updates From ADA 2025

The 2025 ADA Scientific Sessions in Chicago were absolutely packed with groundbreaking announcements and innovations in diabetes care. Highlights included a new tubeless insulin pump, Abbott’s upcoming dual glucose-ketone sensor, and even an implantable continuous glucose monitor (CGM). Tandem and Beta Bionics also shared updates on their CGM integrations and follower app development, while Sequel MedTech officially announced the launch of its twiist insulin pump this week—a customizable system based on the open-source Loop algorithm.

The research side was just as exciting. Experts shared promising progress in cell therapies, ultra-concentrated insulins, and even new hormone-based treatments like amylin co-therapy. There were also updates on extended-wear infusion sets, which are showing not just convenience benefits, but actual improvements in time in range and insulin absorption. One of the most discussed topics? The dual glucose-ketone sensor from Abbott, which could help users proactively detect pump failures or missed insulin doses—potentially preventing dangerous situations before they even begin.

We dive into all of this and more in the latest episode of the Diabetech podcast, where I’m joined by the always-insightful Gary Scheiner, CDCES and clinical director of Integrated Diabetes Services. Gary helps break down the science, shares his top takeaways from the event, and explains how these new innovations could soon reshape diabetes care. Watch the episode below, or listen above (or on your favorite podcast platform. And for updates the latest diabetes tech and news, join our newsletter.

If you’re enjoying our content, consider joining Diabetech All Access—our premium membership with exclusive stories and in-depth industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.